Rafi Allos


Rafi specialises in life sciences patents litigation and advising clients on regulatory issues in the life sciences sector. 

Rafi's patent litigation experience includes both representing clients in U.K. proceedings and assisting clients with multi-jurisdictional proceedings and preparation for potential litigation. In addition, Rafi has a particular interest on the interplay between life sciences regulatory issues and patent litigation and in regulatory exclusivities.

Rafi has spoken on life sciences regulatory matters at the Pharmaceutical Law Academy in Cambridge from 2014 to 2017. He has been recognised since 2017 as a "rising star" in the Patents section of Managing Intellectual Property's IP Stars and as a Next Generation Lawyer/Rising Star in Legal 500 (both in Life Sciences and Healthcare and in Patents). Rafi was also awarded a European Rising Star Award in the Life Sciences and UK categories in the Euromoney LMG Europe Rising Star Awards 2019.


Representative matters

A global pharmaceutical and healthcare company on UK patent and SPC litigation to secure FTO for Taltz® with respect to anti-IL-17A/F antibody patents.

Global pharmaceutical company on the defence of its blockbuster monoclonal antibody against biosimilar competition, on regulatory exclusivities and SPC issues.

A global pharmaceutical and healthcare company on UK and European litigation in relation to Keytruda® against BMS/Ono’s patent covering anti-PD1 antibodies.

Global pharmaceutical company on innovator patent disputes in multiple jurisdictions involving its blockbuster monoclonal antibody drug.

Global pharmaceutical company on the defence of its blockbuster small molecule drug against generic competition in the UK.

A European pharmaceutical company on its patent litigation strategy, co-ordinating six European jurisdictions.

LEO Pharma on the defence of its patents on Dovobet® (calcipotriol/betamethasone ointment) for the treatment of psoriasis.

Various life sciences companies on regulatory matters including on data exclusivity issues; routes for obtaining marketing authorisations; biosimilars; the regulation of clinical trials; compassionate use programmes; paediatric rewards; SPCs; parallel imports; the Specific Mechanism; borderline products; and the medical devices regulatory regime.

Leadership Positions And Professional Affiliations

Solicitor-Advocate (Higher Courts Civil Proceedings), 2018

Admitted as solicitor, England and Wales, 2013

Legal 500 UK 2020: Pharmaceuticals and biotechnology (Rising Star)
destined to be a quite exceptional figure in this field
Legal 500, 2022: Life Sciences and Healthcare (Rising Star)



BA (First Class Hons), Jurisprudence (Law), University of Oxford, 2009

Postgraduate Diploma in Intellectual Property Law and Practice (Distinction), University of Oxford, 2014

A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.